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Although the production of single gene knockout viruses is a useful strategy to study viral gene
functions, the redundancy of many host interactive genes within a complex viral genome can obscure
their collective functions. In this study, a rabbit-speciﬁc poxvirus, myxoma virus (MYXV), was genetically
altered to disrupt multiple members of the poxviral ankyrin-repeat (ANK-R) protein superfamily, M-T5,
M148, M149 and M150. A particularly robust activation of the NF-κB pathway was observed in A549 cells
following infection with the complete ANK-R knockout (vMyx-ANKsKO). Also, an increased release of IL-
6 was only observed upon infection with vMyx-ANKsKO. In virus-infected rabbit studies, vMyx-ANKsKO
was the most extensively attenuated and produced the smallest primary lesion of all ANK-R mutant
constructs. This study provides the ﬁrst insights into the shared functions of the poxviral ANK-R protein
superfamily in vitro and in vivo.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Myxoma virus (MYXV), a rabbit-speciﬁc poxvirus, is both an
effective vertebrate pest control agent and a promising oncolytic
virus candidate (Chan et al., 2013; Kerr, 2012). MYXV, like other
poxviruses, has a dsDNA genome ﬂanked with terminal-inverted
repeats that is packaged within a large brick-shaped virion. The
terminal-inverted repeats and ﬂanking genomic regions contain a
large number of immunoregulatory and/or host range genes,
which are responsible for determining viral tropism and disease
characteristics (Spiesschaert et al., 2011). The functions of numer-
ous MYXV host range genes have been previously reported.
In general, the functions of their gene products can be categorized
as anti-apoptotic, NF-κB regulators, anti-inﬂammasome, cytokine
inhibitors, signaling modulators, blockers of leukocyte activation
or chemotaxis, and serine protease inhibitors (Rahman et al.,
2009; Spiesschaert et al., 2011). Note that NF-κB signaling can be
either induced or inhibited by poxvirus infection, and this signal-
ing can then be either pro-apoptotic or anti-apoptotic depending
on the context (Joshi et al., 2004; Monks et al., 2004; Rahman and
McFadden, 2011; Thomas et al., 2002; C. Y. Wang et al., 1996).
Ankyrin-repeat (ANK-R) motifs are one of the most prevalent
protein motifs encoded by eukaryotes. Multiple helix-loop-helix
domains within the ANK-R protein unit coalesce and speciﬁcally
interact with a large variety of target proteins (Li et al., 2006).
Despite the ubiquitous presence of ANK-R proteins in eukaryotes,
the ANK-R protein motif is absent in most viruses, except pox-
viruses (Sonnberg et al., 2011). Phylogenetic analysis has revealed
that the poxviral ANK-R protein superfamily members all likely
originated from an ancestral ANK-R protein containing both an
N-terminal ANK-R domain and a C-terminal Poxvirus Repeat of
Ankyrin C-terminus (PRANC) domain (Sonnberg et al., 2011). The
unique arrangement of these two domains has only been observed
in poxviruses, Rickettsia sp. and parasitoid wasps (Werren et al.,
2010). Thus far, multiple poxviruses encode members of this
superfamily, such as the orthopoxvirus K1L, CP77, CP006, and
G1R gene products, have been identiﬁed as inhibitors of the NF-κB
pathway (Chang et al., 2009; Mohamed et al., 2009; Mohamed et
al., 2009; Shisler and Jin, 2004).
The activation of the classical NF-κB pathway is initiated
following the detection of certain pro-inﬂammatory cytokines,
damage associated molecular patterns (DAMPs) or pathogen
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/yviro
Virology
http://dx.doi.org/10.1016/j.virol.2014.06.021
0042-6822/& 2014 Elsevier Inc. All rights reserved.
n Corresponding author. Tel.: þ1 352 273 6852; fax: þ1 352 273 6849.
Virology 464-465 (2014) 134–145
associated molecular patterns (PAMPs) by cellular pattern recogni-
tion receptors. The resultant signaling cascade leads to the
phosphorylation of a key activator kinase, inhibitor of NF-κB kinase
(IKK). The phosphorylation of inhibitor of NF-κB α (IκBα) and p105
by activated IKK leads to their ubiquitination and (complete or
partial) degradation. This degradation allows the NF-κB subunits
p65 and p50 to dimerize in the cytoplasm, translocate to the
nucleus and stimulate the transcription of multiple NF-κB respon-
sive genes. The poxviral ANK-R genes K1L, CP77, CP006 and G1R
encode proteins that inhibit the activation of NF-κB by binding to
or inﬂuencing proteins within this pathway.
Fig. 2. Myxoma virus lacking M-T5 exhibits defective replication in A549 (human
lung carcinoma cell line) and RL-5 (rabbit T-cell line). The ability of vMyx-WT,
vMyx-MT5KO, vMyx-148-150KO, and vMyx-ANKsKO to replicate in various cell
lines is determined by single-step growth analyses (MOI 5). Two MYXV-permissive
cell lines, BSC40 (Monkey kidney) and RK13 (Rabbit kidney) (A and C) and two test
cell lines, human A549 and rabbit RL-5 (B and D) are tested. Viral titers are assessed
by focus formation assay. Values are expressed as the mean FFU per 2500 cells
(7 standard deviation [SD]) from triplicate experiments.
Fig. 1. Construction of ANK-R mutant and revertant myxoma viruses. (A) Using
overlapping PCR and Gateway cloning technology, recombinant plasmids are
synthesized to produce ANK-R mutant and revertant viruses. pDNR222 Δ148-150
DSred2 is designed to replace the MYXV 148–150 locus, excluding 150 bp of the
ﬂanking sequence, with a dsRed2 expression cassette driven by a poxviral early-late
promoter p7.5. pDNR222 M-T5-Rev, containing M-T5 and 500 bp of ﬂanking
genomic MYXV sequence, is used to generate the vMyx-MT5KO revertant virus
and a partial vMyx-ANKsKO revertant virus. To create these plasmids, PCR products
are cloned into pDNR222 using the Gateway Cloning System. To produce the vMyx-
148-150KO revertant and the vMyx-ANKsKO revertant, a 7 kb amplicon is
generated. This PCR product is used directly during infection/transfection to
generate revertant virus. (B) The production of vMyx-MT5KO was previously
described by Mossman et al., 1996. vMyx-148-150KO and vMyx-ANKsKO are
synthesized by infecting BSC40 cells with either vMyx-WT or vMyx-MT5KO,
respectively, followed by transfection with pDNR222 Δ148-150 DSred2. (C) PCR is
performed to conﬁrm the genotypes of the newly synthesized ANK-R mutant
myxoma viruses and revertant viruses. Genotyping primer sequences are listed in
Table 2.
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MYXV encodes four distinct members of the poxviral ANK-R
protein superfamily, called M-T5, M148, M149 and M150. While each
of these proteins possess a different number of N-terminal ANK-R
domains, they all possess a PRANC C-terminal domain, which binds
the cellular adapter protein Skp1 in vitro and in vivo (Werden et al.,
2009). Skp1 is an important member of the cellular Skp1-cullin-F-box
(SCF) complex, which in turn is responsible for ubiquitinating cellular
protein targets that regulate key host pathways (such as cell cycle
regulation) for proteasome-dependent degradation (Bai et al., 1996).
Thus far, at least two functional roles have been uncovered for M-T5.
Early studies have reported that M-T5 helps prevent cell cycle arrest
and apoptosis during MYXV infection (Johnston et al., 2005; Mossman
et al., 1996). M-T5 appears to modulate the cell cycle by acting as an
adapter between the ubiquitination/proteosomal degradation machin-
ery of the cell and the cell cycle regulator p27/Kip1 (Johnston et al.,
2005). vMyx-MT5KO exhibits defective dissemination in rabbits, likely
due to an inability of the M-T5-minus virus to suppress apoptosis
during T-cell infection (Mossman et al., 1996). More recently, M-T5 has
also been found to bind and activate cellular AKT, also known as
Protein Kinase B (PKB), by promoting AKT phosphorylation at serine
473 during MYXV infection of cells where this site is underpho-
sphoylated (Werden et al., 2007; Werden et al., 2009). Much less is
known about the functions of M148, M149 and M150 during viral
infection, although the deletion of individual genes reduces virus
virulence in infected rabbits (Blanie et al., 2009; Camus-Bouclainville
et al., 2004). Some preliminary evidence suggests that M150, also
called Myxoma Nuclear Factor (MNF), might be involved in the
suppression of NF-κB activation (Camus-Bouclainville et al., 2004).
This study provides the ﬁrst in vitro and in vivo comparison
between a poxvirus with a complete deletion of the ANK-R protein
superfamily, and its wild-type (WT) equivalent. In this study,
MYXV constructs lacking all, or a combination of, genes encoding
Fig. 3. Absence of all the ANK-Rs from MYXV stimulates excessive nuclear accumulation of p65 in A549 cells. The cellular localization of the NF-κB subunit p65 is assayed in
A549 cells infected with vMyx-WT, vMyx-MT5KO, vMyx-148-150KO, or vMyx-ANKsKO viruses (MOI 5) at 2, 4, 8, and 12 h post infection. Nuclei (blue) are detected using
DAPI staining. Endogenous p65 (green) is detected through indirect immunoﬂuorescence and ﬂuorescent microscopy analysis. (A) The percentage of total cells with a nuclear
localization of p65 throughout virus infection, out of 100 observed cells, is displayed above.Values are expressed as the mean percentage of cells with a nuclear localization
of p65 (7 standard deviation [SD]) from triplicate experiments. (B) Representative images of A549 cell monolayers at 12 h post mock, vMyx-WT, or vMyx-ANKsKO infection.
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ANK-R proteins were created, puriﬁed and characterized. The
ANK-R Mutant viruses tested in this study are vMyx-MT5KO
(inactivation of both copies of the M-T5 gene that maps within
the TIR region of the vMyx genome), vMyx-148-150KO (deletion of
the entire M148–M149–M150 gene locus near the right TIR), and
vMyx-ANKsKO (loss of both copies of M-T5 plus M148, M149 and
M150). The initial characterization of these viruses was performed
in both a human cell line with a well-characterized and functional
NF-κB pathway (A549) and a rabbit T cell line (Liu et al., 2011;
Mossman et al., 1996; Rahman et al., 2013). Also, an in vivo study
in virus-infected rabbits was completed in order to determine
the overall impact of the ANK-R protein superfamily on MYXV
virulence.
Results
Myxoma virus lacking M-T5 exhibits defective replication in A549 and
RL-5 cell lines
Previous studies have indicated that the ability of vMyx-
MT5KO to replicate in a variety of test mammalian cell lines is
inﬂuenced by the basal level of cellular AKT phosphorylation
and/or a cellular susceptibility to cell cycle arrest (Johnston et al.,
2005; Wang et al., 2006). Since the cellular tropism of vMyx-148-
150KO and vMyx-ANKsKO has not been investigated, single step
growth curves for vMyx-WT, vMyx-MT5KO, vMyx-148-150KO, and
vMyx-ANKsKO were performed in a number of cell lines. Both
BSC40 (monkey kidney) and RK13 (rabbit kidney) cell lines are
known to be highly permissive to MYXV infection. All the viruses
tested demonstrated comparable levels of viral replication and
production of progeny virus in these cells (Fig. 2A and C). This
conﬁrms that these viruses are capable of optimal replication
kinetics under favorable permissive cellular conditions.
The functionality of the NF-κB signaling pathway in the MYXV-
permissive human lung cancer cell line A549 makes it an optimal
model for the study of potential NF-κB pathway modulators, like
the poxviral ANK-R proteins. Single step growth curve analysis
within A549 cells revealed a notable defect in the replication of
MYXV constructs lacking M-T5 (Fig. 2B). The additional deletion of
the M148–M150 gene locus did not further alter the ability of the
recombinant vMyx-ANKsKO to replicate within A549 cells.
An earlier report by Mossman et. al. reported defective vMyx-
MT5KO replication within the rabbit T-cell line, RL5 (Mossman et
al., 1996). To determine whether the newly constructed vMyx-148-
150KO and vMyx-ANKsKO viruses also exhibited defective replica-
tion in RL-5 cells, single-step growth curve analysis was performed
in RL-5 cells. In agreement with the published literature, MYXV
lacking M-T5 displayed a notable defect in replicative ability
within RL-5 cells (Fig. 2D). However, the deletion of M148–M150
alone did not appear to affect virus replication in RL-5 cells,
nor did it further exacerbate the replication defect observed
for the vMyx-MT5KO virus when it was carried within the
vMyx-ANKsKO virus.
NF-κB activation is triggered by infection with ANK-R mutant
myxoma virus constructs
Although several members of the poxviral ANK-R superfamily
have been shown to act as inhibitors of the classical NF-κB
pathway, no previous studies have reported NF-κB stimulation
during in vitro infection with MYXV lacking one or multiple ANK-R
proteins (Mohamed et al., 2009; Mohamed et al., 2009). Since
human A549 cells possess a functional NF-κB pathway and also
exhibit a defect in the replication of MYXV lacking M-T5, the
ability of vMyx-WT and the ANK-R mutant viruses to stimulate the
NF-κB pathway in A549 cells was tested. The translocation of the
endogenous NF-κB subunit p65 from the cytoplasm to the nucleus
of a cell is indicative of the activation of the classical NF-κB
pathway. The nuclear accumulation of p65 in A549 cells after
infection with the various ANK-R mutant viruses was assessed via
immunoﬂuorescence. Overall, vMyx-ANKsKO infection of A549
cells triggered the nuclear accumulation of p65 in a higher
percentage of cells than vMyx-WT, vMyx-MT5KO or vMyx-148-
150KO infections (Fig. 3A). The disparity between the ability of
vMyx-WT and the ANK-R mutant infections to stimulate NF-κB
activation was observed as early as 2 h after infection and was
most dramatic at 12 h post infection. Relative to vMyx-WT infec-
tion, the percentage of A549 cells with nuclear accumulation of
p65 after 12 h of vMyx-MT5KO, vMyx-148-150KO, and vMyx-
ANKsKO virus infection (MOI 5) increased approximately 40, 20,
and 120 folds, respectively. A representative image produced
after immunoﬂuorescence for p65 in A549 cells following 12 h of
mock, vMyx-WT or vMyx-ANKsKO infection is shown (Fig. 3B).
Fig. 4. Kinetics of cytokine secretion in myxoma virus infected A549 cells in vitro.
A549 cells are mock infected, treated with Pam2CSK4 (a TLR4 agonist active for
A549 cells) or infected with vMyx-WT, vMyx-MT5KO, vMyx-148-150KO, or vMyx-
ANKsKO viruses. Cell supernatants are collected at indicated time points to
measure secretion of A) IL-8 and B) IL-6 by ELISA. Values are expressed as mean
cytokine concentration (7 standard deviation [SD]) from triplicate experiments.
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A majority of cells within the monolayer after mock or vMyx-WT
infection exhibit segregation between p65 (green anti-p65 immu-
noﬂourescence) and nuclei (blue DAPI.) In contrast, most cells
within a monolayer infected with vMyx-ANKsKO demonstrate
extensive co-localization between p65 and the nucleus.
Infection with ANKs knockout myxoma virus triggers an increase in
both IL-6 and IL-8 release
Previous studies have reported that the activation of the NF-κB
pathway within A549 cells by various ssRNA viruses leads to the
secretion of IL-8 and/or IL-6 (Arnold et al., 1994; Bao et al., 2007;
Chun et al., 2013; Devhare et al., 2013; Julkunen et al., 2000;
Kanzawa et al., 2006). Interestingly, all the ANK-R mutant MYXV
constructs also stimulate NF-κB activation in A549 cells, but to
varying degrees. Further experiments with ANK-R mutant MYXV
constructs were performed to determine if, as in the case of ssRNA
virus infections, an increased release of IL-8 and/or IL-6 accom-
panies the virus-induced NF-κB stimulation. Following vMyx-
ANKsKO infection, a slight delay in IL-8 and IL-6 protein secretion
occurred relative to the kinetics of NF-κB stimulation. Speciﬁcally,
vMyx-ANKsKO infection led to an increased release of IL-8 at 48,
72 and 96 HPI compared to vMyx-WT infection (Fig. 4A). vMyx-
ANKsKO infection also stimulated an increased secretion of IL-6 at
72 and 96 HPI (Fig. 4B). In contrast, vMyx-148-150KO infection
did not stimulate the release of IL-6. However, vMyx-148-150KO
infection did increase the release of IL-8 at 72 and 96 HPI.
Unexpectedly, vMyx-MT5KO infection did not promote the secre-
tion of either IL-8 or IL-6 (Fig. 4A and B). If anything, the secretion
of IL-8 and IL-6 appears to be reduced in vMyx-MT5KO infected
cells relative to vMyx-WT infected cells.
Infection of A549 cells with myxoma virus lacking M-T5 results in
excessive cytotoxicity and apoptosis
Early studies of M-T5 have described the anti-apoptotic func-
tion of M-T5 in vitro (Johnston et al., 2005). In order to determine
the effect of ANK-R mutant MYXV infections on cell viability,
trypan blue exclusion assays, MTT assays and TUNEL assays were
performed at various time points post infection. At both 24 and 48
HPI, vMyx-MT5KO and vMyx-ANKsKO infection caused a 5 fold
increase in cytotoxicity relative to vMyx-148-150KO or vMyx-WT
infection, as measured by the exclusion of trypan blue (Fig. 5A).
Curiously, during infection with all tested myxoma viruses, the
MTT assay detected a similar decrease in the quantity of active
mitochondrial metabolism in A549 cells at 24 and 48 HPI (Fig. 5B).
This could indicate that viable cells infected with vMyx-WT or
vMyx-148-150KO exhibit retarded proliferation. By 72 HPI, the
number of cells with actively metabolic mitochondria does begin
to decrease during infection with vMyx-MT5KO and vMyx-
ANKsKO, relative to vMyx-148-150KO or vMyx-WT infection.
While the trypan blue exclusion assay gives a rough estimate
of cell viability as assessed by cell membrane permeability, it does
not specify the mechanism of cell death and often overestimates
cytotoxicity. TUNEL assays were performed to determine if
virus-induced apoptosis contributes to the number of dead cells
observed during vMyx-MT5KO and vMyx-ANKsKO infection
(Fig. 6A and B). As expected, A549 cells infected with vMyx-
MT5KO or vMyx-ANKsKO underwent more apoptosis than cells
infected with vMyx-WT or vMyx-148-150KO (Fig. 6B). Interest-
ingly, the proportion of cells undergoing apoptosis is 2-fold higher
during infection with vMyx-MT5KO relative to vMyx-ANKsKO.
This suggests that, while M-T5 reduces the level of apoptosis
in infected cells, one or more members of the M148–M150
family might in fact contribute to the virus-mediated induction
of apoptosis.
ANK-R knockout myxoma virus infection of NZW rabbits is severely
attenuated
in vivo infection studies in NZW rabbits were previously
reported for vMyx-MT5KO, vMyx-148KO, vMyx-149KO, vMyx-
150KO, and vMyx148-149KO MYXV constructs (Blanie et al., 2009;
Camus-Bouclainville et al., 2004; Mossman et al., 1996). Each of
these viruses were attenuated, in varying degrees, relative to
vMyx-WT infection. At the time of writing, no previous reports
have examined the impact of selectively deleting the entire ANK-R
protein superfamily on poxviral virulence. In this study, vMyx-
148-150KO (lacking the three unique single copy ANK-R genes)
and vMyx-ANKsKO (mutant for all 5 ANK-R genes) were tested for
virulence in NZW rabbits. vMyx-WT, vMyx-MT5KO, vMyx-MT5KO
Rev, vMyx-148-150KO Rev and vMyx-ANKsKO Rev infections were
also performed in parallel. In congruence with previous ﬁndings,
vMyx-WT and all the revertant MYXV inoculations of NZW rabbits
resulted in a rapid, wide-spread and fatal infection. Within
four days of inoculation of vMyx-WT and the revertant MYXVs,
Fig. 5. Detection of cytotoxicity following infection with ANK-R mutant myxoma
viruses. (A) A549 cells are mock infected or infected with vMyx-WT, vMyx-MT5KO,
vMyx-148-150KO, or vMyx-ANKsKO viruses and cell membrane integrity, as a
surrogate for cell death, is detected by trypan blue exclusion assay. Values are
expressed as the mean percentage of trypan blue-positive cells (7 standard
deviation [SD]) from triplicate experiments. (B) Cell viability as assessed by
mitochondrial function levels following infection is measured by MTT assay. Results
are displayed as mean absorbance (7 standard deviation [SD]) from triplicate
experiments.
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a sizable primary lesion and minute secondary lesions (5/8 rabbits)
were apparent (Table 4). By the seventh day of infection, the
lesions became more severe and numerous. Also, the majority of
these infected rabbits developed a mucosal bacterial infection (7/8).
Ultimately, at 9–10 days post inoculation, the animals had to be
euthanized due to the increasing severity of clinical symptoms,
according to IACUC regulations (Table 3). Comparatively, vMyx-
148-150KO infection was much less severe than vMyx-WT or
revertant infections (Fig. 7B). More speciﬁcally, the size/number
of lesions and the severity of the mucosal bacterial infections
were diminished during vMyx-148-150KO infection. Despite this
attenuation, vMyx-148-150KO infection displayed a similar pro-
gression of symptoms within the ﬁrst 7 DPI as WT or revertant
infections. However, while vMyx-WT infection symptoms rapidly
intensiﬁed after 7 days, vMyx-148-150KO infection began showing
signs of healing after 7 DPI and all rabbits recovered fully within
17 DPI.
Mossman et. al. previously determined that vMyx-MT5KO
infection in NZW rabbits exhibited both reduced lesion size and
an almost complete absence of viral dissemination to secondary
sites (Mossman et al., 1996). In this study, our observations during
vMyx-MT5KO infection were consistent with this previous report
(Table 4, Fig. 7A). Overall, these in vivo observations demonstrate
that knocking out M-T5 alone produced a more severe viral
attenuation than knocking out M148, M149 and M150 individually
or together (Blanie et al., 2009; Camus-Bouclainville et al., 2004;
Mossman et al., 1996). Since M148 KO, M149 KO, M150 KO
and MT5KO MYXV constructs were all attenuated in rabbits,
Fig. 6. DNA fragmentation analysis of A549 cells following infection with ANK-R mutant myxoma viruses. Fragmented DNA in ANK-R mutant myxoma virus infected cells is
labeled with BrdU and used as a marker for apoptosis. A) A graphical representation of anti-BrdU APC labeled cells (10,000 events) at 48 h post mock infection or infection
with vMyx-WT (GFP), vMyx-MT5KO (GFP), vMyx-148-150KO (DSred2), and vMyx-ANKsKO (DSred2). B) The mean percentage of TUNEL-positive cells (7 standard deviation
[SD]) from triplicate experiments at both 24 and 48 HPI with ANK-R mutant myxoma viruses.
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vMyx-ANKsKO was predicted to also be attenuated. Indeed, in vivo
ANKs KO infection produced smaller primary lesions than either
vMyx-148-150KO or vMyx-MT5KO infection (Fig. 7A). Also, vMyx-
ANKsKO, like vMyx-MT5KO, was defective in systemic viral dis-
semination (Table 4).
Discussion and conclusions
This study reports that the MYXV gene M-T5 is required for the
optimal replication of the virus in both human A549 and in rabbit
RL-5 cells (Fig. 2). This defective replication was associated with
excessive cytotoxicity and apoptosis in A549 cells during infection
with MYXV lacking M-T5 (Fig. 5A, Fig. 6B). These ﬁndings are
consistent with an earlier study that demonstrated defective
MYXV replication and apoptosis in rabbit RL-5 cells infected with
vMyx-MT5KO (Mossman et al., 1996). In contrast, the triple
deletion of M148–M149–M150 from MYXV had no effect on viral
replication or cell viability in either of these cell lines. Thus, the
ability of M-T5 to prevent apoptosis, as measured by the TUNEL
assay, appears to be unique among the poxviral ANK-R proteins
encoded by MYXV. Interestingly, the vMyx-ANKsKO virus induces
less apoptosis than the vMyx-MT5KO (Fig. 6B), suggesting that,
while M-T5 inhibits the induction of apoptosis, one or members of
the M148-M150 family might in fact be virus-encoded stimulators
of apoptosis.
Prior to this study, a number of poxviral ANK-R proteins and
cellular ANK-R proteins have been shown to prevent the activation
of NF-κB signaling (Basith et al., 2013; Mohamed et al., 2009;
Mohamed et al., 2009; Rahman and McFadden, 2011). This study
provides the ﬁrst evidence that MYXV ANK-R proteins block NF-κB
activation during late stages of infection. Relative to vMyx-WT
infection, vMyx-MT5KO, vMyx-148-150KO and vMyx-ANKsKO
infection, at 12 HPI, increased the percentage of A549 cells that
exhibit nuclear accumulation of the NF-κB p65 subunit by 40, 20
and 120 fold, respectively (Fig. 3A). Since p65 migration from the
cytoplasm to the nucleus is a classical indicator for the activation
of the NF-κB signaling cascade, these data indicate that the
collective function of the MYXV ANK-R proteins is to block or
reduce NF-κB activation in infected cells. The dramatic increase in
the number of NF-κB-stimulated cells after vMyx-ANKsKO infec-
tion, relative to both vMyx-MT5KO and vMyx-148-150KO, indi-
cates that there is some redundancy in the ability of MYXV ANK-R
proteins to prevent NF-κB activation during virus infection. Thus,
the deletion of the entire ANK-R superfamily is necessary to
investigate the cumulative impact of these viral proteins on NF-κB
repression.
Thus far, we have shown that ANK-R mutant MYXV infection
can both activate NF-κB and engender virus-induced apoptosis.
This joint activation of NF-κB and increased cell death upon viral
infection has also been observed after infection of A549 cells with
ssRNA viruses, such as Respiratory Syncytial Virus and Inﬂuenza A
virus (Thomas et al., 2002; Tripathi et al., 2013) These previous
studies have also observed an increased secretion of IL-8 and IL-6
after viral infection. In this study, vMyx-ANKsKO infection, but not
vMyx-MT5KO infection, was found to stimulate the release of both
IL-8 and IL-6 in A549 cells (Fig. 4A and B). Preliminary evidence
suggests that both vMyx-MT5KO and vMyx-ANKsKO infection also
increases IL-6 and IL-8 gene expression in the rabbit T-cell line
RL-5 (data not shown).
Given the ability of ANK-R mutant MYXV constructs to trigger
deﬁned anti-viral pathways like the classical NF-κB pathway and
the apoptotic pathway in vitro, it is reasonable to hypothesize
that these viruses will also be more susceptible to overall anti-
viral responses in infected rabbits in vivo. Previously, the reduced
secondary spread of vMyx-MT5KO in vivo was shown to be
reﬂected by the induction of apoptosis in rabbit T-cells upon
infection with vMyx-MT5KO (Mossman et al., 1996). Similarly,
vMyx-ANKsKO infection does not spread beyond the primary
lesion (Table 4). Although both vMyx-MT5KO and vMyx-ANKsKO
are restricted to the primary site of infection, the primary lesion
produced during vMyx-ANKsKO infection was notably smaller
than the lesion produced by vMyx-MT5KO infection (Fig. 7A).
Thus, vMyx-ANKsKO could be even further limited by additional
anti-viral responses within the primary lesion.
This study provides the ﬁrst evidence that NF-κB activation can
be simultaneously suppressed by multiple poxviral ANK-R pro-
teins. A variety of in vivo studies have demonstrated that pox-
viruses unable to properly suppress NF-κB activity are often
attenuated in the infected host (Harte et al., 2003; Mohamed et
al., 2009; Rahman et al., 2009; Stack et al., 2005). Further in vitro
infection studies in primary rabbit cells and histological studies in
NZW rabbits will be required to conﬁrm that the increased
activation of the NF-κB pathway is a key in situ target that
contributes to vMyx-ANKsKO attenuation in vivo.
This study demonstrates that vMyx-ANKsKO induces a greater
innate immune response in vitro than vMyx-WT or the other
tested ANK-R mutant constructs. Given the close link between
Fig. 7. Attenuation of myxoma virus virulence during ANK-R mutant infection of
rabbits. NZW rabbits are inoculated intradermally with 1000 FFU of vMyx-WT
(n¼2), vMyx-MT5KO (n¼3), vMyx-148-150KO (n¼4), vMyx-ANKsKO (n¼4) and
the various revertant MYXVs (n¼3 each). (A) Calipers are used to measure primary
lesion diameter throughout the course of virus infection. Values are expressed as
the mean lesion diameter (7 standard deviation [SD]). Lesions with exceptionally
small diameters, e.g. during initial growth or late recovery are excluded from this
chart. (B) After daily physical examinations, clinical scores for infected rabbits are
calculated based on abnormal respiration, weight, temperature, heart rate, lung
sounds, food and water intake, urine and feces output, hydration status, attitude,
posture, indications of primary lesion and appearance of secondary lesions. Values
are expressed as the mean clinical score (7 standard deviation [SD]).
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innate immune stimulation and the acquisition of long-term
acquired immunity, we propose that the vMyx-ANKsKO virus
will also induce higher levels of cellular and/or humoral immune
responses. In the ﬁeld of oncolytic virotherapy, a concerted
effort has been undertaken to generate safe oncolytic viruses that
trigger an enhanced immune response to tumoral antigens that
become revealed by virtue of virus replication within tumor beds
(Russell et al., 2012). These newer-generation viruses, through
selective infection and replication within tumors, must also
counteract the immunosuppressive microenvironment frequently
found within most tumors. Previous clinical trials have shown that
some oncolytic viruses capable of eliciting anti-tumoral immune
responses also increase serum levels of multiple pro-inﬂammatory
cytokines, including IL-6 (Kirn, 2001; Prestwich et al., 2008; Zeh
and Bartlett, 2002). Additional studies will be required to deter-
mine if the apparently pro-immunogenic vMyx-ANKsKO virus is
also an effective oncolytic virus that also favors increased immune
responses to tumor antigens.
Materials and methods
Cell lines
Monkey cell line BSC-40 (ATCC# CRL-1658), human cell line
A549 (ATCC# CCL-185), and rabbit cell line RK13 (ATCC# CCL-37)
were maintained in Dulbecco's Modiﬁed Eagle Medium (DMEM;
Invitrogen) supplemented with 10% fetal bovine serum (FBS;
Gibco), 2 mM L-glutamine, and 100 U/mL of penicillin/streptomy-
cin (pen/strep; Invitrogen). RL-5 cells were cultured in RPMI 1640
medium (Lonza, BioWhittaker) supplemented with 10% FBS, 2 mM
L-glutamine, and 100 U/mL of pen/strep. All cultures were main-
tained in a humidiﬁed chamber at 37 1C and 5% CO2. The BSC40
monkey kidney cell line was received as a gift from Richard Condit
from the University of Florida. During maintenance, cell cultures
were periodically tested to conﬁrm the absence of contaminating
mycoplasma species, using a PCR-based assay (Southern Biotech
#13100-01)
Viral preparation
All viruses used in this study were grown and ampliﬁed in
BSC40 cells. Viruses were puriﬁed by centrifugation through a
sucrose cushion as described previously (Smallwood et al., 2010).
The viruses in this study were titered in BSC40 cells or in
RK13 cells.
Construction of recombinant viruses
The production of vMyx-MT5KO was described previously
(Mossman et al., 1996). Two novel ANK-R mutant viruses, vMyx-
148-150KO and vMyx-ANKsKO, and three revertant viruses,
Table 1
Nomenclature and characteristics of ANK-R knockout myxoma viruses.
Virus name Abbreviation Genetic alterations
vMyx-WT Lausanne vMyx-WT Lau N/A
vMyx-WT LacZ GFP vMyx-WT Intergenic p11 LacZ between M010 and M011
Intergenic EL GFP between M135 and M136
vMyx-MT5KO LacZ GFP Eco GPT vMyx-MT5KO Intergenic p11 LacZ between M010 and M011
Intergenic EL GFP between M135 and M136
Intragenic EL Eco GPT within M-T5
vMyx-M148/M149/150KO DSred2 vMyx-148-150KO EL DSred2 replacing M148–M150
vMyx-MT5KO/M148/M149/ M150KO LacZ Eco GPT DSred2 vMyx-ANKsKO Intergenic p11 LacZ between M010 and M011
Intragenic EL Eco GPT within M-T5
EL DSred2 replacing M148–M150
vMyx-MT5KO revertant vMyx-MT5KO Rev Intergenic EL GFP between M135 and M136
Intergenic p11 LacZ between M010 and M011
vMyx-M148/M149/150KO revertant vMyx-148-150 KO Rev N/A
vMyx-MT5KO/M148/M149/M150-KO revertant vMyx-ANKsKO Rev Intergenic EL GFP between M135 and M136
Intergenic p11 LacZ between M010 and M011
EL-Vaccinia Virus synthetic early/late promoter p7.5.
P11-vaccinia Virus late promoter.
Table 2
Primer sequences used to create and genotype recombinant myxoma virus.
Primer name Sequence
attB1_F GGGGACAAGTTTGTACAAAAAAGCAGGCTCCACC
attB2_R GGGGACCACTTTGTACAAGAAAGCTGGGTCCAA
1_attB1M147F AAAGCAGGCTCCACCACCAGTGTTTTATACACAAAGGAG
2_5M148ELF GGATTATCTAAAGAAAGAACTCTGCAGGTCGACTCTAG
3_RED3M150R CGATGGCTTGAATGTTAGAATTCGAGCTCGGTAC
4_M151R ACAAGAAAGCTGGGTCCAAGCTGTCGTACCGAACTCGGTC
attB1_MT5F AAAGCAGGCTCCACCCTCGATAATCGCGAGTACATTTTC
attB2_MT5R ACAAGAAAGCTGGGTCCAAGATTCCGGACGTGGAATATTGGAC
M147_F_full_attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCTCCACCACCAGTGTTTTATACACAAAGGAG
M151_R_full_attB2 GGGGACCACTTTGTACAAGAAAGCTGGGTCCAAGCTGTCGTACCGAACTCGGTC
M149GenotypingF AGACGTCCGGGTAGAACGTTGA
M149GenotypingR TGTGGAACTCCGGACACACGGT
M147GenotypingF ACAACGCGACAACTGCCGAC
M151GenotypingR TGCCCTCGTTCCTCACGTCCA
MT5GenotypingF TGTCGTGTACGCCTCGTATC
MT5GenotypingR TTGAACCGTCGCTTGTGTAG
S.A. Lamb et al. / Virology 464-465 (2014) 134–145 141
vMyx-MT5KO Rev, vMyx-148-150KO Rev, and vMyx-ANKsKO Rev,
were produced during the course of this study (Table 1). Either
recombinant plasmids or recombinant PCR products were con-
structed to hybridize with speciﬁc regions of the MYXV genome.
(Fig. 1A) To generate vMyx-148-150KO and vMyx-ANKsKO, the
construct pDNR222 Δ148-150 DSred2 was created. Overlapping
PCR was used to ﬂank a DSred2 expression cassette, driven by a
synthetic poxviral early/late promoter, with 1 kb of hybridizing
sequence (Chakrabarti et al., 1997). These ﬂanking sequences were
selected to facilitate the replacement of the M148, M149, and
M150 locus of MYXV with a DSred2 expression cassette. The
primers used for the ampliﬁcation of this recombinant PCR
product contained ﬂanking attB sequences that enabled the
insertion of the PCR product into the Gateway cloning donor
vector pDNR222 (Invitrogen) (Table 2) (Fig. 1A). vMyx-148-150KO
and vMyx-ANKsKO were created by infecting BSC40 cells with
either vMyx-WT or vMyx-MT5KO, respectively, followed by trans-
fection with pDNR222 Δ148-150 DSred2 (Fig. 1B). Multiple rounds
of foci puriﬁcations were performed based on DSred2 expression
and continued until pure foci were isolated and conﬁrmed by PCR
using appropriate primers (Fig. 1C and Table 2).
After ANK-R mutant MYXV constructs were puriﬁed and
conﬁrmed, revertant viruses were made from each knockout virus.
The M-T5 sequence in vMyx-MT5KO and vMyx-ANKs-KO was
restored by infecting a selectively permissive cell line Caki1, which
favors vMyx-WT replication, and subsequently cotransfecting both
pBS135–136eGFP (described previously) and a revertant plasmid
containing the complete M-T5 sequence with 500 bp ﬂanking
genomic sequence (Fig. 1A and B) (Chakrabarti et al., 1997;
Johnston et al., 2003). Multiple rounds of foci puriﬁcation were
performed based on both foci size and eGFP expression.
The 148–149–150 locus was reintroduced into vMyx-148-
150KO and the Partial ANKs KO revertant MYXVs through the
infection of BSC40 cells followed by transfection with a PCR
product containing the ORFs M148–M150 and 1000 bp of ﬂanking
genomic sequence (Fig. 1A). vMyx-148-150KO revertant viruses
were puriﬁed in RK13 cells through many rounds of clear plaque
selection. The complete vMyx-ANKsKO revertant underwent mul-
tiple rounds of foci puriﬁcation in BSC40s based on eGFP expres-
sion in the absence of DSred2 expression. The purity of all newly
constructed viruses was conﬁrmed by PCR using appropriate
primers (Fig. 1A and Table 2).
Table 3
Criteria for scoring virus-infected rabbits
Assessments Points
0 1 2 4
Posture Normal
Sitting erect, ears up,
moving freely, lying
stretched out.
Abnormal
Some reduction in spontaneous activity, will move
with gentle encouragement but prefers to be
inactive. Change in posture.
Very abnormal
Little to no spontaneous activity.
Eating and drinking Normal Abnormal
Reduced intake.
Very abnormal
Minimal intake.
Attitude Normal
Bright and alert, interested
in surroundings; usual
temperament.
Abnormal
A bit dull but still active in investigating new
situation, objects placed in pen.
Very abnormal
Very dull, not interested in
surroundings, preoccupied.
Hydration Normal
No tent or twist.
Abnormal
Tent, but returns to shape after o30 s.
Very abnormal
Tent and does not return to shape
readily.
Eyes Normal Abnormal
Conjunctivitis either unilateral or bilateral. May have
occasional nodules. Eyes are not closed.
Very abnormal
Severe conjunctivitis with purulent
discharge. Eyes may be partially
closed. Lids swollen.
Nose Normal Abnormal
Some swelling or discharge either purulent or
purulohaemorrhagic.
Very abnormal
Severe swelling and/or profuse
discharge.
Respiration Normal Abnormal
410% difference from daily average
in uninfected.
Very abnormal
420% difference
from daily average
in uninfected.
Ears Normal Abnormal
Some swelling or discharge either purulent or
purulohaemorrhagic.
Very abnormal
Severe swelling and/or profuse
discharge.
Heart rate Normal
180–250 bpm
Abnormal
140–180 bpm
Very abnormal
o140 bpm
Temperature Normal
101.3–1041F
Abnormal
104.1–1061F
Very abnormal
41061F
Weight Normal Constant weight
gain.
Abnormal
No weight gain.
Very abnormal
Weight loss.
Feces Normal
Normal amount and
consistency.
Abnormal
Reduced amount or alteration in consistency.
Very abnormal
Minimal elimination or very liquid
feces.
Injection site Normal
No swelling/ reaction at
site.
Abnormal
Ulceration and/or diffuse reaction.
Very abnormal
Severe swelling of lesion, necrosis,
etc.
Viremia (secondary
lesions other than
nose, ear and eye)
Normal
No secondary lesions
present.
Abnormal
Secondary lesions present, minimal.
Very abnormal
Secondary lesions
present, severe.
Conditions which require immediate euthanasia.
If a rabbit reaches a score of 26/34, or should it exhibit any of the following conditions, it will be euthanized immediately.
1. Orthopnea 2. Mouth breathing 3. Cyanosis 4. Essentially no food or water intake 448 h.
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Single-step growth curves
Cells were seeded into 24-well dishes in semi-conﬂuent mono-
layers (1.25105 cells) and infected with vMyx-WT or the ANK-R
mutant viruses at an MOI of 5 for 1 h. After 1 h of incubation, the
innoculum was removed, the cell monolayer was washed with PBS
and fresh complete media was added to the monolayer. Samples
were collected at various times post-infection and stored at
80 1C until processed. The samples were freeze-thawed at
80 1C and 37 1C three times and sonicated for 1 min to release
virus from infected cells. The virus was titrated on BSC40 cells by
serial dilution in triplicate. After 48 h of infection, ﬂuorescent foci
were counted and the viral titer was calculated.
Immunoﬂuorescence
On rat collagen-coated coverslips, MYXV-permissive human
A549 cells (5103) were seeded and either mock infected or
infected with vMyx-WT, vMyx-MT5KO, vMyx-148-150KO, or
vMyx-ANKsKO for 1 h at 37 1C. After removal of the innoculum,
the monolayers were washed with PBS and covered in fresh
media. At speciﬁed time points post infection, coverslips were
washed with PBS and ﬁxed with 4% paraformaldehyde (Sigma) for
15 min at 4 1C. The ﬁxative was then discarded and excess
paraformaldehyde was removed by washing 3 with cold PBS.
The coverslip was then blocked with blocking buffer (5% FBS þPBS
þ0.3% TritonX-100) for 1 h at RT. In order to detect the NF-κB p65,
the coverslip was incubated with rabbit anti-p65 (sc-372;
Santa Cruz) diluted 1:100 in Antibody dilution buffer (1X PBS, 3%
BSA/0.3% TritonX 100) overnight at 4 1C. Residual primary anti-
body was removed by three 15 min washes with PBS. A 2 h RT
incubation with Alexaﬂuor 488 (green) goat anti-rabbit antibody
diluted 1:1000 in Antibody dilution buffer was performed next.
Another set of PBS washes was executed to remove excess
secondary antibody. After p65 labeling, coverslips were mounted
on microscope slides with 7.5 mL Vecta-shield hard mounting
media with DAPI (40,6 diamidino-2-phenylindole; Vector Labora-
tories) for the visualization of nuclei. Cells were viewed using the
Leica inverted ﬂuorescent microscope. The localization of p65
was recorded for 100 cells per sample. Using these data, the
percentage of total cells exhibiting a nuclear localization of p65
was calculated.
ELISA
A549 cells (5105) were seeded in 6 well plates. The following
day, the cells were mock infected, infected with vMyx-WT, vMyx-
MT5KO, vMyx-148-150KO or vMyx-ANKsKO (at MOI of 5), or
treated with the TLR agonist Pam2CSK4, which is known to
stimulate NF-κB activation in these cells. Supernatants were
collected at speciﬁed time points post infection. The concentration
of IL-6 and IL-8 in the supernatants was determined using Ready-
Set-Go!s ELISA assay kits (eBioscience) following the manufac-
turer's protocol.
Trypan blue exclusion assays
For trypan blue exclusion assays, A549 cells (5105) were
seeded into 6 well plates. The following day, the cells were either
mock infected or infected with vMyx-WT, vMyx-MT5KO, vMyx-
148-150KO or vMyx-ANKsKO (at MOI of 5). Both detached cells in
the supernatant and trypsinized adherent cells were pooled
together. After the cells were pelleted and resuspended in 250 μL
of fresh media, the samples were incubated at room temperature
for 15 min in a 0.2% solution of trypan blue dye (Sigma). Cytotoxi-
city was calculated as the percentage of cells permeated with
trypan blue divided by the total number of cells.
Table 4
Pathogenesis of ANK-R KO vMyxs in New Zealand White (NZW) rabbits.
Day vMyx-WT and revertants vMyx-MT5KO vMyx-148-150KO vMyx-ANKsKO
0 Inoculation of two rabbits
intradermally with 1000 PFU or FFU
for each of the following viruses:
vMyx-WT Lausanne, vMyx-MT5KO
revertant, vMyx 148-150 revertant,
vMyx-ANKsKO revertant.
Inoculation of three rabbits
intradermally with 1000 FFU of
vMyx-MT5KO.
Inoculation of four rabbits
intradermally with 1000 FFU of
vMyx-148-150KO.
Inoculation of four rabbits
intradermally with 1000 FFU of
vMyx-ANKsKO.
4 Primary lesions at inoculation sites:
2.0–3.0 cm (8/8).
Primary lesions at inoculation sites:
raised, soft, red (ca 2.0–2.5 cm)
(3/3).
Primary lesions at inoculation sites:
raised, soft, red (ca 2.0–2.5 cm) (4/4).
Primary lesions at inoculation
sites: raised, soft, red (ca 1.5-
2.5 cm)
(4/4).
Raised, soft, red lesions (4/8). One rabbit exhibited minute
secondary lesions on the ear.Raised, red, necrotic lesions (4/8).
Multiple secondary lesions on ears
(5/8).
7 Primary lesions red, swollen,
necrotic (4.0–5.0 cm) 8/8.
Primary lesions red, swollen,
necrotic, healing (2.0–2.5 cm) (3/3).
Primary lesions red, swollen,
necrotic (ca 3.5–5.0 cm) (4/4).
Primary lesions red, swollen,
necrotic
(ca 1.5–2.0 cm) (4/4).Multiple secondary myxomas in the
eyes, ears, and nose (8/8).
Multiple minute secondary
myxomas (4/4), gram-negative
bacterial infections of conjunctivas
(2/4).
Gram-negative bacteria infections
of conjunctivas (7/8).
9–10 Primary lesions red, swollen,
necrotic
(5.0–6.0 cm) (8/8).
Primary lesions swollen, but healing. Primary lesions swollen, but healing. Primary lesions swollen, but
healing.Secondary lesions healing (4/4).
Multiple secondary myxomas,
turning necrotic, dyspnea, severe
infections of respiratory tracts,
prostrated and emaciated animals.
All rabbits were sacriﬁced due to
the severity of symptoms.
17 Full regression of primary lesions. Full regression of primary and
secondary lesions.
Full regression of primary lesions.
S.A. Lamb et al. / Virology 464-465 (2014) 134–145 143
MTT cell proliferation assays
The relative quantity of viable, proliferating cells after infec-
tion was estimated by measuring mitochondrial function using
CellTiter 96 Non-Radioactive Cell Proliferation Assay (MTT,
Promega). A549 cells (5.0103) were seeded into 96-well
dishes and infected with vMyx-WT or the ANK-R mutant viruses
(MOI 5) at 24, 48, and 72 h prior to the execution of the MTT
assay. After the ﬁrst hour of infection, the innoculum was
removed, the cell monolayer was washed with PBS and fresh
complete media was added. The MTT assay was performed
according to the manufacturer's instructions. Each treatment
was performed in triplicate and the results provide an indication
of the relative quantity of viable/proliferating cells after the
different treatments.
TUNEL assay
The proportion of cells undergoing apoptosis during ANK-R
mutant virus infection was determined using TUNEL staining
to monitor nuclear DNA degradation and ﬂow cytometric analysis.
A549 cells (1106) were seeded into 6 well plates. The follow-
ing day, the cells were either mock infected or infected with
vMyx-WT, vMyx-MT5KO, vMyx-148-150KO or vMyx-ANKsKO
(MOI of 5). Both detached cells in the supernatant and trypsinized
adherent cells were collected and pooled together. Fragmented
DNA, a marker for apoptotic cell death, was stained using the
in situ Direct DNA Fragmentation (TUNEL) Assay Kit (Abcam,
ab66108) according to the manufacturer's protocol. Anti-BrdU
APC antibody (eBioscience) was used instead of anti-BrdU Red to
allow the simultaneous detection of BrdU and DSred2. The cells
were then characterized using a FACScalibur (Becton Dickinson)
and analyzed by CELLQuest software. The collected data was
analyzed using FCS Express 4 Flow Cytometry software (De Novo
Software).
Rabbit experiments
New Zealand White rabbits were purchased from Charles
River Laboratories International. This animal study was approved
by the Institutional Animal Care and Usage Committee (IACUC)
at the University of Florida. This study was performed as
described previously (Liu et al., 2011). Brieﬂy, 1000 focus-
forming units (FFU) of the tested virus was resuspended in
100 ml of PBS and inoculated intradermally in the left ﬂank of
each rabbit. Daily physical examinations were performed to
evaluate the condition of the rabbits by monitoring respiration,
temperature, heart rate, weight, attitude, lung sound, food and
water intake, urine and feces output, hydration status, posture,
indications of primary lesion and the appearance of secondary
lesions (Table 3). The rabbits receive a daily clinical score (from
0 to 34) that is dependent on observations collected during the
daily evaluation. The animals were humanely euthanized when
the clinical score reached 26 to 34, had open mouth breathing
due to respiratory stress, orthopnea, cyanosis or no food and
water intake for 48 h.
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